How do you approach post-transplant maintenance for patients with high-risk myeloma?
Which PI and at what dosing intervals? Dexamethasone or not?
Emory has now published data with VRd consolidation as well as KPd consolidation, while FORTE has looked at KR. Which PI do you use, and q1wk or q2wk? Would you use MASTER-guided decision-making in certain patients even if they haven't received D-KRd upfront?
Community PollStarted
What maintenance therapy do you recommend for high-risk myeloma post-transplant?
12 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on
I'm migrating the discussion from another thread ("Top Takeaways from ASCO 2023") here, mainly because the premise of this question is based on new data about KPd maintenance in high-risk patients presented by Dr. Nooka and colleagues as an oral presentation this past ASCO 2023.
@Dr. First Last's ins...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on
I think these thoughts make good sense, but I want to clarify what is high risk and what we know. I also don't think we should ever withhold effective therapy if it's available, in favor of 'saving it for later'; patients die with each relapse and hence we shouldn't save anything.
My definition of hi...
Join for free or sign in to see the full answer